- From: Matthias Samwald <samwald@gmx.at>
- Date: Tue, 15 Feb 2011 07:09:41 +0100
- To: "Eric Prud'hommeaux" <eric@w3.org>, <public-semweb-lifesci@w3.org>
- Cc: "Helena Deus" <helenadeus@gmail.com>
Hi Eric, I'm not an expert, but this seems a bit hard to answer. Bapineuzumb does not seem to bind or directly regulate Apolipoprotein and its variants. The APOE4 allele is merely a biomarker which can be used to stratify the patient population into likely responders and non-responders. Looking at the HCLS KB, TMKB and http://lod.openlinksw.com, the (almost) only information that can be found about Bapineuzumab are clinical trials from LinkedCT. hypothesis.alzforum.org does not have much either, unfortunately. - Matthias -------------------------------------------------- From: "Eric Prud'hommeaux" <eric@w3.org> Sent: Monday, February 14, 2011 10:37 PM To: <public-semweb-lifesci@w3.org> Cc: "Helena Deus" <helenadeus@gmail.com> Subject: beefing up PharmaOntology Queries #Q6 > Query six¹ matches patients without the APOE4 allel, putatively to > match the inclusion criterial for a clinical trial involving > Bapineuzumab. Do we have any drug data which links Bapineuzumab to > APOE4, so that we query for *any* protein regulated by Beelzebub, > rather than specifically APOE4? > > > ¹ > http://www.w3.org/wiki/HCLSIG/PharmaOntology/Queries#Q6._Are_there_any_AD_patients_without_the_APOE4_allele_as_these_would_be_good_candidates_for_the_clinical_trial_involving_Bapineuzumab.3F > > -- > -ericP >
Received on Tuesday, 15 February 2011 06:10:21 UTC